ECWM-1

Study Design: Phase III, randomized, multicenter, international trial

Patients: treatment naive WM patients

Treatment: DRC versus Bortezomib-DRC

Status of the Study: Patient recruitment: closed (last patient in Sept 2018, n = 202)

Sponsor: University Hospital of Ulm, PI Christian Buske